Abstract
The expansion of trinucleotide CAG repeat sequences has been shown to be the underlying cause of eight human neurodegenerative disorders, including Huntington’ s disease (HD), spinal and bulbar muscular atrophy (SBMA), dentatorubral-pallidoluysian atrophy (DRPLA), Machado-Joseph disease (MJD), and the spinocerebellar ataxias (SCAs)(for review see refs. [1–3]). These diseases are progressive disorders characterized by motor and/or cognitive impairments and distinctive pathological patterns of neuronal degeneration within the central nervous system (CNS). Each is caused by CAG codon expansion within a unique gene producing a polyglutamine (polyGln) tract enlargement in the target protein (4–6). All of these neurodegenerative disorders present a common feature: the accumulation of the polyGln repeat disease-related protein into neuronal intranuclear inclusions, which have become the neuropathological signature of polyGln disorders (7–9). Several lines of reasoning suggest strongly that the expanded polyGln tract is itself responsible for the pathogenesis. First, the disease-related proteins do not present any homology in either size or amino acid composition outside of the expanded polyGln tract (6,10–12). Second, the severity of the disease increases with the length of the polyGln repeat. Third, the length of the polyGln sequence that triggers increased risk for developing the pathology is very similar for almost of these diseases (2,13,14). Finally, transgenic animals expressing protein fragments with an expanded polyGln repeat exhibit neurodegenerative phenotypes reminiscent of disease symptoms (15–19).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cummings, C. J. and Zoghbi, H. Y. (2000) Fourteen and counting: unraveling trinucle-otide repeat diseases. Hum. Mol. Genet. 9, 909–916.
Evert, B. O., Wullner, U., and Klockgether, T. (2000) Cell death in polyglutamine diseases. Cell Tissue Res. 301, 189–204.
Zoghbi, H. Y. and Orr, H. T. (2000) Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217–247.
Hackam, A. S., Singaraja, R., Wellington, C. L., Metzler, M., McCutcheon, K., Zhang, T., et al. (1998) The influence of huntingtin protein size on nuclear localization and cellular toxicityJ.CellBiol. 141, 1097–1105.
MacDonald, M. E. and Gusella, J. F. (1996) Huntington’s disease: translating a CAG repeat into a pathogenic mechanism. Curr. Opin. Neurobiol. 6, 638–643.
Paulson, H. L., Perez, M. K., Trottier, Y., Trojanowski, J. Q., Subramony, S. H., Das, S. S., et al. (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19, 333–344.
Davies, S. W., Turmaine, M., Cozens, B. A., Raza, A. S., Mahal, A., Mangiarini, L., and Bates, G. P. (1999) From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington’s disease Philos. Trans. R. Soc. Lond. B. Biol. Sci. 354, 981–989.
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990–1993.
Yamada, M., Tsuji, S., and Takahashi, H. (2000) Pathology of CAG repeat diseases. Neuropathology 20, 319–325.
Becker, M., Martin, E., Schneikert, J., Krug, H. F., and Cato, A. C. (2000) Cytoplasmic localization and the choice of ligand determine aggregate formation by androgen receptor with amplified polyglutamine stretch. J. Cell. Biol. 149, 255–262.
Holmberg, M., Duyckaerts, C., Durr, A., Cancel, G., Gourfinkel-An, I., Damier, P., et al. (1998) Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum. Mol. Genet. 7, 913–918.
Li, S. H. and Li, X. J. (1998) Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Hum. Mol. Genet. 7, 777–782.
Harper, P. S. and Newcombe, R. G. (1992) Age at onset and life table risks in genetic counselling for Huntington’s disease. J. Med. Genet. 29, 239–242.
Schelhaas, H. J., Ippel, P. F., Hageman, G., Sinke, R. J., van der Laan, E. N., and Beemer, F. A. (2001) Clinical and genetic analysis of a four-generation family with a distinct autosomal dominant cerebellar ataxia. J. Neurol. 248, 113–120.
Abel, A., Walcott, J., Woods, J., Duda, J., and Merry, D. E. (2001) Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum. Mol. Genet. 10, 107–116.
Ikeda, H., Yamaguchi, M., Sugai, S., Aze, Y., Narumiya, S., and Kakizuka, A. (1996) Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat. Genet. 13, 196–202.
Li, H., Li, S. H., Cheng, A. L., Mangiarini, L., Bates, G. P., and Li, X. J. (1999) Ultrastruc-tural localization and progressive formation of neuropil aggregates in Huntington’ s disease transgenic mice. Hum. Mol. Genet. 8, 1227–1236.
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493–506.
Satyal, S. H., Schmidt, E., Kitagawa, K., Sondheimer, N., Lindquist, S., Kramer, J. M., and Morimoto, R. I. (2000) Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 97, 5750–5755.
McCampbell, A., Taylor, J. P., Taye, A. A., Robitschek, J., Li, M., Walcott, J., et al. (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 9, 2197–2202.
Nucifora, F. C., Jr., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423–2428.
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y. Z., Gohler, H., et al. (2000) The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 97, 6763–6768.
Scherzinger, E., Sittler, A., Schweiger, K., Heiser, V., Lurz, R., Hasenbank, R., et al. (1999) Self-assembly of polyglutamine-containing huntingtin fragments into amyloid like fibrils: implications for Huntington’s disease pathology. Proc. Natl. Acad. Sci. USA 96, 4604–4609.
Esler, W. P., Stimson, E. R., Jennings, J. M., Vinters, H. V., Ghilardi, J. R., Lee, J. P., et al. (2000) Alzheimer’s disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 39, 6288–6295.
Chen, S. and Wetzel, R. (2001) Solubilization and disaggregation of polyglutamine peptides. Protein Sci. 10, 887–891.
Chen, S., Berthelier, V., Wang, W., and Wetzel, R. (2001) Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol. 311, 173–182.
Berthelier, V., Hamilton, J. B., Chen, S., and Wetzel, R. (2001) A microtiter plate assay for polyglutamine aggregate extension. Anal. Biochem. 295, 227–236.
McGowan, D. P., van Roon-Mom W., Holloway, H., Bates, G. P., Mangiarini, L., Cooper, G. J., et al. (2000) Amyloid-like inclusions in Huntington’s disease. Neuroscience 100, 677–680.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Berthelier, V., Wetzel, R. (2003). An Assay for Characterizing In Vitro the Kinetics of Polyglutamine Aggregation. In: Potter, N.T. (eds) Neurogenetics. Methods in Molecular Biology™, vol 217. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-330-5:295
Download citation
DOI: https://doi.org/10.1385/1-59259-330-5:295
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-990-2
Online ISBN: 978-1-59259-330-9
eBook Packages: Springer Protocols